Herbal medicine for immunotherapy-related rash
Part of Skin clinical trials.
This study tests whether adding a Chinese herbal medicine to your current treatment can help with the rash that often comes from immunotherapy drugs. It is an extra treatment on top of your regular care, aiming to improve your skin comfort without changing your cancer therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must be receiving cancer treatment with immune checkpoint inhibitors (immunotherapy drugs).
- You must have developed a rash that is related to your immunotherapy treatment.
- You must not have any other active skin conditions that could interfere with judging the rash.
- You must not be allergic to any ingredient in the study herbal formula.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 1 trial tests whether rituximab (a drug that targets certain immune cells) can help reduce side effects caused by immunotherapy. The goal is to find a safe dose and see if it improves symptoms without harming your cancer treatment.
This study tests a new cream, ATR04-484, to see if it can help with skin rashes caused by certain cancer medications (EGFR inhibitors, KRAS inhibitors, or MEK inhibitors). If you have a moderate to severe rash on your face or other areas from these drugs, this trial may offer a new way to ease your symptoms.
This trial tests whether an herbal formula called Qibei Jiedu can help prevent or reduce the severity of skin irritation (radiation dermatitis) caused by radiation therapy in breast cancer patients. It focuses on people who meet specific traditional Chinese medicine criteria and can be used alongside standard radiation treatment.
This trial tests a traditional Chinese medicine approach using an herbal formula and acupoint patches to help people with both allergic rhinitis and asthma during a quiet phase. It focuses on a pattern called 'yang deficiency' and may offer an alternative or addition to standard care.
This study tests a new pill (a JAK inhibitor) for people with severe skin rashes from cancer immunotherapy that did not improve with standard treatments. The goal is to see if the drug can safely ease the rash.
This trial tests a medicated foam (roflumilast) to relieve skin problems like rash, itching, or eczema that can happen during immune checkpoint inhibitor cancer treatment. The goal is to see if the foam helps clear the skin without needing steroid creams or pills.
Hear when a new Immune Checkpoint Inhibitor-related Rash trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.